U.S. FDA approves first respiratory syncytial virus vaccine

LOS ANGELES, May 3 (Xinhua) -- The U.S. Food and Drug Administration (FDA) approved the first respiratory syncytial virus (RSV) vaccine on Wednesday.

The vaccine, named Arexvy, is approved for the prevention of lower respiratory tract disease caused by RSV in individuals 60 years of age and older.